1. Pink Sheet
  2. >>Market Access

Part D Plans Bracing For Wegovy; Strict Prior Authorizations To Prevent Obesity Use Are Likely

 
• By Cathy Kelly

Despite worries about potential costs of inadvertently covering Wegovy for obesity because of patient (and physician) gaming, Novo’s new CV claim expected to garner wide formulary adoption. Since coverage for weight loss drugs is still prohibited in Medicare, CMS may issue guidance.

Access To Wegovy Likely To Be Tightly Controlled • Source: Shutterstock

Medicare Part D sponsors are expected to cover Novo Nordisk’s Wegovy for its newly-approved indication for cardiovascular risk reduction in patients with obesity but will look to prior authorizations to block reimbursement for obesity alone.

Plans may be worried that the cardioprotective indication gives Wegovy (semaglutide) a foot in the door that patients will try to exploit to gain Part D coverage for obesity,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Few Takers For EMA’s OPEN Pathway Prompts Rethink

 
• By Vibha Sharma

While drug companies say they support the European Medicines Agency’s expanded OPEN framework for the collaborative assessment of marketing applications with non-EU authorities, they are reluctant to participate in the initiative for a number of reasons.

EU Council Could Adopt Pharma Reform Package Next Week, But Disputes Risk A Year’s Delay

 
• By Eliza Slawther

The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.